太极集团清理“两资两非”聚焦主业 10.8万元挂牌转让阿依达泉水40%股权

Core Viewpoint - Taiji Group is divesting its 40% stake in Aida Company to focus on its core pharmaceutical business and optimize resource allocation [1][2] Group 1: Transaction Details - Taiji Group's subsidiary, Fuling Pharmaceutical, plans to transfer its 40% stake in Aida Company through a public listing, with an initial listing price of 108,000 yuan [1] - The valuation of Aida Company is based on a professional assessment, with total equity valued at 270,000 yuan as of August 31, 2025, making the 40% stake worth 108,000 yuan [1] - Aida Company has faced operational challenges, reporting total assets of 123 million yuan, total liabilities of 152 million yuan, and a net asset deficit of 28.96 million yuan as of August 31, 2025 [1] Group 2: Financial Impact - The initial investment cost for the stake in Aida Company was 47.5 million yuan, but due to continuous losses, the investment's book value has been reduced to zero as of December 31, 2024 [2] - The divestment is not expected to significantly impact Taiji Group's current profits, as the primary goal is to clean up non-core assets and enhance management efficiency [2] Group 3: Strategic Focus - Taiji Group aims to continue its strategy of focusing on its core business, enhancing operational quality and management efficiency to create greater value for shareholders [3]